TG Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Tuesday, January 12, 2021 at 2:00 PM ET
Author:
Publish date:

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) - Get TG Therapeutics, Inc. Report today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference, being held virtually. The presentation is scheduled to take place on Tuesday, January 12, 2021 at 2:00 PM ET.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events. A replay of the webcast will be available on TG's website following the event.

ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing multiple therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon. Umbralisib is currently under review by the U.S. Food and Drug Administration (FDA) for accelerated approval as a treatment for patients with previously treated marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen or follicular lymphoma (FL) who have received at least two prior systemic therapies. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its Bruton's Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeutics is headquartered in New York City.

CONTACT:

                  Jenna A. Bosco                  Senior Vice President,                   Corporate Communications                  TG Therapeutics, Inc.                  Telephone: 212.554.4351                  Email: ir@tgtxinc.com